Tyler, Alan
October 2004
European Chemical News;10/11/2004, Vol. 81 Issue 2119, p28
Trade Publication
Presents news briefs on the fine chemicals industry as of October 11, 2004. Value of the contract awarded by the U.S. National Institutes of Health to Bavarian Nordic for the development of a smallpox vaccine; Implication of a new grade of carbon nanofibre developed by Japanese firm Showa Denko for the electronics industry; Percent increase in the global prices of brominated fine chemicals implemented by Albermarle.


Related Articles

  • GOVERNMENT OF CANADA PROCURES IMVAMUNE SMALLPOX VACCINE.  // Worldwide Biotech;Jan2009, Vol. 21 Issue 1, p6 

    The article reports on the contract awarded by Public Works and Government Services Canada to Bavarian Nordic in January 2009 for the delivery of Imvamune, a Modified Vaccinia Ankara (MVA)-based, third generation smallpox vaccine. As stated, the procurement will be used by the Canadian...

  • Battling Bioterror.  // Pharmaceutical Executive;Oct2004, Vol. 24 Issue 10, p21 

    Reports on a contract awarded by the United States government to Acambis and Bavarian Nordic to develop and produce a Modified Vaccinia Ankara smallpox vaccine. Value of the deal; Reduction of complications in the weaker version of the vaccine.

  • Bavarian's Smallpox Vaccine Pact Worth Up To $1.6 Billion. Sheridan, Cormac // BioWorld International;6/6/2007, Vol. 12 Issue 23, p1 

    The article reports on the contract won by Bavarian Nordic A/S to supply a stockpile of next-generation safe smallpox vaccines to the U.S. Department of Health and Human Services. The pharmaceutical company is expected to earn a total of $1.6 billion from the contract. The vaccine produced by...

  • Bavarian Lands $545M Deal For Smallpox Vaccine Stockpile. Sheridan, Cormac // BioWorld International;4/18/2007, Vol. 12 Issue 16, p1 

    The article announces that Bavarian Nordic A/S is poised to land a contract to supply the U.S. government with a stockpile of 20 million doses of its next-generation smallpox vaccine Imvamune. The value of the deal is mentioned. Bavarian Nordic's rival company is Acambis plc. Comments from Rolf...

  • US extends Imvamune smallpox vaccine trials.  // PharmaWatch: Biotechnology;Dec2007, Vol. 6 Issue 12, p4 

    The article reports on the extension of an existing contract provided by the U.S. government with Bavarian Nordic AS to include a larger Phase II study with Imvamune. The drug is the company's investigational smallpox vaccine for persons diagnosed with atopic dermatitis. According to the report,...

  • Danish Biopharma Company Secures $500-Million U.S. Contract. Scott, Alex // Chemical Week;6/20/2007, Vol. 169 Issue 21, p31 

    The article highlights the announcement of the U.S. Department of Health and Human Services (HHS) that it had agreed to contract out the manufacture of 20 million doses of smallpox vaccine to biopharmaceutical company Bavarian Nordic for $500 million. The value of the groundbreaking deal could...

  • HHS Ordering 20 Million Doses Of Bavarian Nordic's Imvamune. Boggs, Jennifer // BioWorld Today;4/17/2007, Vol. 18 Issue 74, p1 

    The article reports on the plan of the U.S. Department of Health and Human Services to buy 20 million doses of the Imvamune vaccine from Bavarian Nordic A/S. It might be the first contract award under the U.S. RFP-3, a request for proposals for modified vaccinia ankara (MVA)-based vaccine for...

  • Showa Denko K.K. SWOT Analysis.  // Showa Denko K.K. SWOT Analysis;12/31/2015, p1 

    A SWOT analysis of Showa Denko K.K. is presented.

  • Showa Denko K.K. SWOT Analysis.  // Showa Denko K.K. SWOT Analysis;5/30/2019, p1 

    A SWOT analysis of Showa Denko K.K. is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics